TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00576849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced HES 130/0.42
Description: Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced HES 130/0.42
Description: Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% HES 130/0.4 prepared in saline solution
Description: Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Study: NCT02306018

Intervention type: DEVICE
Intervention: EV1000™/volumeView™
Study: NCT01803464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude vibration
Description: Children will receive a daily low-magnitude vibration treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Children who are candidates to receive Botox as part of their standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Children who are candidates to receive Botox as part of their standard of care.
Study: NCT00580931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: 1500 mg twice a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enduramide placebo
Description: 1 tab twice a day
Study: NCT01262274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: ANA is given 1mg daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole plus tegafur-uracil
Description: ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
Study: NCT01802762

Intervention type: DEVICE
Group type: OTHER
Intervention: NeMo Patch and NeMo Probe
Description: A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
Study: NCT03162861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane inhalation for anesthesia
Description: The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol for anesthesia
Description: The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
Study: NCT03808896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stylet-assisted epiglottic lifting
Description: use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bougie-assisted intubation
Description: use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
Study: NCT03142477

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapeutic touch
Description: Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Description: Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
Study: NCT01548573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV or PO
Study: NCT00673452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: 60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
Study: NCT00813124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on day 0 administered by vein after collected from donor.
Study: NCT03262272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIE A Hemodialyzer
Description: polysulfon membrane coated with vitamin E

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIE A Hemodialyzer
Description: polysulfon membrane coated with vitamin E

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rexsys 27H hemodialyzer
Description: polyethersulfon membrane with large surface area : 2,7m²

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rexsys 27H hemodialyzer
Description: polyethersulfon membrane with large surface area : 2,7m²

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leoceed 21HX hemodialyzer
Description: polyslfon membrane with gamma sterilization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leoceed 21HX hemodialyzer
Description: polyslfon membrane with gamma sterilization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypure 22S+ hemodialyzer
Description: polysulfon membrane with steam sterilization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypure 22S+ hemodialyzer
Description: polysulfon membrane with steam sterilization
Study: NCT00733824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Study: NCT04929561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-conferencing group
Description: No intervention
Study: NCT01248117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 2.0mg
Description: Monthly, intravitreal injection 0.05ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 2.0mg
Description: Monthly, intravitreal injection 0.05ml
Study: NCT02538926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT01548573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT02538926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02168166

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Executive Function Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo version of executive function training
Study: NCT05267067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory exercises
Description: Manual respiratory exercises versus respiratory exercises with pressure meter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory exercises
Description: Manual respiratory exercises versus respiratory exercises with pressure meter
Study: NCT02035007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCCO Catheter (Pulsiocath 5F)
Description: Measuring of PiCCO derived values
Study: NCT03198273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates exercises
Description: servical, lumbal, pelvic muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy program
Description: hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
Study: NCT00260234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cultured Islet Cells (human); Encapsulated
Study: NCT01374113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg safinamide
Description: 50 mg safinamide on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg safinamide
Description: 50 mg safinamide on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg safinamide
Description: 50 mg safinamide on Day 1
Study: NCT00410696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: 5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg/day sc at day +1
Study: NCT01228240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT00881075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SeeMore(TM)
Description: single dose intravenous injectable
Study: NCT01548573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study: NCT02050373

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level laser
Description: Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
Study: NCT00978640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fast and exercise
Description: fasting 36 h and exercise 1 h 50% VO2max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise 1 h 50% VO2max
Study: NCT01570127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized Acupuncture
Description: The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Waiting
Description: No interventions were applied to the patients in this group.
Study: NCT02237066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chocolate PTA Balloon Angioplasty
Description: OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA Balloon Angioplasty
Description: OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
Study: NCT03508466

Intervention type: BEHAVIORAL
Intervention: hypersensitivity reaction
Description: Previous hypersensitivity reaction

Intervention type: BEHAVIORAL
Intervention: hypersensitivity reaction
Description: Previous hypersensitivity reaction
Study: NCT03716440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature exposure
Description: Participants will view images of nature.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-nature exposure
Description: Participants will view non-nature images.
Study: NCT01807910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl-D9-choline
Description: Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl-D9-choline
Description: Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
Study: NCT04332874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolated Limb Infusion
Description: ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of melphalan and dactinomycin
Description: infusion of melphalan and dactinomycin
Study: NCT03092115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIV medication adherence app
Description: A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
Study: NCT01626209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
Study: NCT03469882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein nutrition
Description: Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometry exercise
Description: Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care group
Description: Participants randomized to the usual care group will receive usual care protein and exercise.
Study: NCT03144115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT02512991

Intervention type: OTHER
Intervention: Helicopter Emergency Medical Service
Description: May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
Study: NCT03853980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Contouring System
Description: Single treatment of skin resection (removal of loose skin)
Study: NCT00381667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444H
Description: H salt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT01411475

Intervention type: OTHER
Intervention: Bifurcation restenosis classification
Description: Classification of restenosis involving coronary bifurcation according to their pattern
Study: NCT03922321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401
Description: RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
Study: NCT00155311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Study: NCT02052024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYOBLOC
Description: Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
Study: NCT03154541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synrinse
Description: Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synrinse
Description: Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
Study: NCT00015964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Study: NCT02522689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Ultra-mini PCNL will be performed.
Study: NCT01816334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Study: NCT02522689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Micro PCNL will be performed.